An announcement from Innovent Biologics ( (HK:1801) ) is now available.
Innovent Biologics, Inc. has announced changes in its board’s nomination committee and the designation of a lead independent non-executive director, effective March 31, 2025. Ms. Joyce I-Yin Hsu has been appointed as a member of the nomination committee, while Mr. Shuyun Chen has been designated as the lead independent non-executive director, reflecting the company’s ongoing efforts to strengthen its governance structure.
More about Innovent Biologics
Innovent Biologics, Inc. is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. It is listed on the Stock Exchange of Hong Kong and operates with a group of subsidiaries.
YTD Price Performance: 27.73%
Average Trading Volume: 14,200
Technical Sentiment Signal: Sell
Current Market Cap: $9.73B
Find detailed analytics on 1801 stock on TipRanks’ Stock Analysis page.